Paper Details

Paper Title

Purifying Selection against Pathogenic Mitochondrial DNA in Human T Cells.

Paper Journal Title

N Engl J Med

Paper Citation Count

Paper Publication Year

2020

Bio Mention

A3243G, Human, Human T Cells, Pathogenic Mitochondrial DNA, Patients, T cells, blood cells, lactic acidosis, mitochondrial DNA, mitochondrial diseases, mtDNA, mutant, mutant mtDNA, patient, patients, strokelike, strokelike episodes

Mesh Descriptor

Author Name	Affiliation
Amel Karaa	Massachusetts General Hospital, Howard Hughes Medical Institute (M.A.W., Boston Children's Hospital (C.A.L., Dana-Farber Cancer Institute, Harvard Medical School (C.A.L., Harvard Medical School (V.K.M.), and Harvard Medical School (M.A.W., Broad Institute of MIT (Massachusetts Institute of Technology) and Harvard (M.A.W., the Harvard Stem Cell Institute (V.G.S.), and the Department of Biology and Koch Institute of Integrative Cancer Research, Massachusetts Institute of Technology (A.R.)
Vijay G Sankaran	Massachusetts General Hospital, Howard Hughes Medical Institute (M.A.W., Boston Children's Hospital (C.A.L., Dana-Farber Cancer Institute, Harvard Medical School (C.A.L., Harvard Medical School (V.K.M.), and Harvard Medical School (M.A.W., Broad Institute of MIT (Massachusetts Institute of Technology) and Harvard (M.A.W., the Harvard Stem Cell Institute (V.G.S.), and the Department of Biology and Koch Institute of Integrative Cancer Research, Massachusetts Institute of Technology (A.R.)
Aviv Regev	Massachusetts General Hospital, Howard Hughes Medical Institute (M.A.W., Boston Children's Hospital (C.A.L., Dana-Farber Cancer Institute, Harvard Medical School (C.A.L., Harvard Medical School (V.K.M.), and Harvard Medical School (M.A.W., Broad Institute of MIT (Massachusetts Institute of Technology) and Harvard (M.A.W., the Harvard Stem Cell Institute (V.G.S.), and the Department of Biology and Koch Institute of Integrative Cancer Research, Massachusetts Institute of Technology (A.R.)
Aviv Regev	Massachusetts General Hospital, Howard Hughes Medical Institute (M.A.W., Boston Children's Hospital (C.A.L., Dana-Farber Cancer Institute, Harvard Medical School (C.A.L., Harvard Medical School (V.K.M.), and Harvard Medical School (M.A.W., Broad Institute of MIT (Massachusetts Institute of Technology) and Harvard (M.A.W., the Harvard Stem Cell Institute (V.G.S.), and the Department of Biology and Koch Institute of Integrative Cancer Research, Massachusetts Institute of Technology (A.R.)
Vamsi K Mootha	Massachusetts General Hospital, Howard Hughes Medical Institute (M.A.W., Boston Children's Hospital (C.A.L., Dana-Farber Cancer Institute, Harvard Medical School (C.A.L., Harvard Medical School (V.K.M.), and Harvard Medical School (M.A.W., Broad Institute of MIT (Massachusetts Institute of Technology) and Harvard (M.A.W., the Harvard Stem Cell Institute (V.G.S.), and the Department of Biology and Koch Institute of Integrative Cancer Research, Massachusetts Institute of Technology (A.R.)
Vamsi K Mootha	Massachusetts General Hospital, Howard Hughes Medical Institute (M.A.W., Boston Children's Hospital (C.A.L., Dana-Farber Cancer Institute, Harvard Medical School (C.A.L., Harvard Medical School (V.K.M.), and Harvard Medical School (M.A.W., Broad Institute of MIT (Massachusetts Institute of Technology) and Harvard (M.A.W., the Harvard Stem Cell Institute (V.G.S.), and the Department of Biology and Koch Institute of Integrative Cancer Research, Massachusetts Institute of Technology (A.R.)

1 - 6

Paper Details

Column Actions

Datasets